FDA approved Rocuronium Bromide Injection for Tracheal Intubation and Muscle RelaxationFDA approved new muscle relaxant Rocuronium Bromide for surgery and breathing support.

FDA From the archive Source published June 9, 2025 Summary added July 18, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Individualize dosing and use peripheral nerve stimulator to monitor neuromuscular blockade with Rocuronium Bromide Injection.

The FDA has approved Rocuronium Bromide Injection, a nondepolarizing neuromuscular blocking agent, as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. The approval provides an additional option for clinicians managing airway and muscle relaxation needs in surgical and critical care settings. The drug should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with neuromuscular blocking agents. Dosing must be individualized, and a peripheral nerve stimulator is recommended to monitor drug response and guide additional doses.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent. It acts by competing with acetylcholine for binding to nicotinic cholinergic receptors at the neuromuscular junction, thereby blocking neuromuscular transmission.

Indication & Patient Population

Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Dosing & Administration

Rocuronium Bromide Injection is for intravenous use only. The recommended initial dose for tracheal intubation is 0.6 mg/kg. For rapid sequence intubation, doses of 0.6 to 1.2 mg/kg are used. Maintenance doses of 0.1, 0.15, or 0.2 mg/kg are administered at 25% recovery of control T1. Continuous infusion should start at 10 to 12 mcg/kg/min only after early evidence of spontaneous recovery from an intubating dose. Dosing should be individualized and guided by response; a peripheral nerve stimulator is recommended.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Accidental administration of neuromuscular blocking agents may be fatal. Store Rocuronium Bromide Injection with cap and ferrule intact to minimize the risk of selecting the wrong product. Dose adjustment should be considered in patients with anticipated potentiation or resistance to neuromuscular block. See label for specific drug interactions and use in special populations.

Place in Therapy

Rocuronium Bromide Injection provides an additional option for neuromuscular blockade during anesthesia and mechanical ventilation. Its dosing flexibility allows for use in both routine and rapid sequence intubation. Clinicians should be familiar with its use and monitor neuromuscular function closely.

The FDA has approved a new drug called Rocuronium Bromide Injection. It is a muscle relaxant used during surgery or when a patient needs a breathing tube. The drug helps doctors place the tube quickly and keeps muscles relaxed during the procedure or while on a ventilator.

This medicine is only for use in hospitals or surgical centers. It must be given by a doctor or trained healthcare professional. The dose is tailored to each patient, and a device called a nerve stimulator is often used to check how the drug is working.

This approval gives doctors another option to manage muscle relaxation in critical care and surgery. It does not mean the drug is available for home use or over the counter. It is a powerful medicine that requires close monitoring.

If you are having surgery or need a breathing tube, your healthcare team will decide if this drug is right for you. Talk to your doctor if you have questions about muscle relaxants or anesthesia. They can explain the risks and benefits based on your health needs.

What this means for you:

Rocuronium Bromide is a hospital only muscle relaxant for surgery and breathing support. Talk to your doctor.

Study Details

Study typeFda approval

PublishedJun 2025

View Original Abstract ↓

1 INDICATIONS AND USAGE Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )

FDA approved Rocuronium Bromide Injection for Tracheal Intubation and Muscle RelaxationFDA approved new muscle relaxant Rocuronium Bromide for surgery and breathing support.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

FDA approved Rocuronium Bromide Injection for Tracheal Intubation and Muscle RelaxationFDA approved new muscle relaxant Rocuronium Bromide for surgery and breathing support.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties